HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Kiniksa Pharmaceuticals Ltd (KNSA) Stock Price, Analysis & Trade Signals

$51.89+0.31 (+0.60%)

Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. Its pipeline of potential treatments includes ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor, aimed at addressing recurrent pericarditis, an inflammatory heart condition. Also in development is Mavrilimumab, a monoclonal antibody inhibitor that has successfully concluded Phase II clinical trials for managing giant cell arteritis. Ad…

Market Cap
$3.53B
CEO
Sanj K. Patel
Employees
315
IPO Date
2018-05-25
Website
www.kiniksa.com

Tabs · Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics